JP2004505617A5 - - Google Patents

Download PDF

Info

Publication number
JP2004505617A5
JP2004505617A5 JP2002516300A JP2002516300A JP2004505617A5 JP 2004505617 A5 JP2004505617 A5 JP 2004505617A5 JP 2002516300 A JP2002516300 A JP 2002516300A JP 2002516300 A JP2002516300 A JP 2002516300A JP 2004505617 A5 JP2004505617 A5 JP 2004505617A5
Authority
JP
Japan
Prior art keywords
reagent
trp8b
trp8a
trp10b
trp10a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2002516300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004505617A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/008309 external-priority patent/WO2002010382A2/en
Publication of JP2004505617A publication Critical patent/JP2004505617A/ja
Publication of JP2004505617A5 publication Critical patent/JP2004505617A5/ja
Ceased legal-status Critical Current

Links

JP2002516300A 2000-07-28 2001-07-18 Ｔｒｐ８、Ｔｒｐ９およびＴｒｐ１０、癌の新規マーカー Ceased JP2004505617A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22151300P 2000-07-28 2000-07-28
PCT/EP2001/008309 WO2002010382A2 (en) 2000-07-28 2001-07-18 Trp8, trp9 and trp10, markers for cancer

Publications (2)

Publication Number Publication Date
JP2004505617A JP2004505617A (ja) 2004-02-26
JP2004505617A5 true JP2004505617A5 (enExample) 2005-03-03

Family

ID=22828139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002516300A Ceased JP2004505617A (ja) 2000-07-28 2001-07-18 Ｔｒｐ８、Ｔｒｐ９およびＴｒｐ１０、癌の新規マーカー

Country Status (8)

Country Link
US (1) US7205108B2 (enExample)
EP (1) EP1366158B1 (enExample)
JP (1) JP2004505617A (enExample)
AT (1) ATE396266T1 (enExample)
AU (1) AU2001287639A1 (enExample)
CA (1) CA2417671A1 (enExample)
DE (1) DE60134178D1 (enExample)
WO (1) WO2002010382A2 (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364867B2 (en) 2000-04-17 2008-04-29 The Mount Sinai School Of Medicine Method of identifying bitter compounds by employing TRP8, a transient receptor potential channel expressed in taste receptor cells
DE10215321A1 (de) * 2002-04-02 2003-10-23 Metagen Pharmaceuticals Gmbh Trp-p8 Splice Varianten und regulatorische RNA
US20050176010A1 (en) * 2002-04-16 2005-08-11 Bayer Healthcare Ag Regulation of human transient receptor potential channel
US20060188990A1 (en) * 2002-04-19 2006-08-24 Schering Aktiengesellschaft Novel prostate tumor-specific promoter
JP4431503B2 (ja) * 2003-01-08 2010-03-17 株式会社東京大学Ｔｌｏ カルシウム吸収を促進する因子
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US8399201B2 (en) 2005-10-31 2013-03-19 Janssen Pharmaceutica N.V. Polypeptide complex of TRPM8 and calmodulin and its uses thereof
EP2268665B1 (en) 2008-03-19 2014-11-12 Soricimed Biopharma Inc. Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity
JP5836940B2 (ja) 2009-06-26 2015-12-24 ソリシメド・バイオファーマ・インコーポレーテッド ソリシジン由来ペプチドならびにｔｒｐｖ−６がんの検出および薬剤送達のための方法
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2640727B1 (en) 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
JP6104257B2 (ja) 2011-10-14 2017-03-29 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンおよびそのコンジュゲート
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
KR101995620B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
PT2906253T (pt) 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
WO2014133120A1 (ja) 2013-02-28 2014-09-04 株式会社ニチレイバイオサイエンス 標識酵素を用いた染色用ｄａｂ含有基質キット
MX363787B (es) 2013-03-13 2019-04-03 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de los mismos.
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
BR112016012410A2 (pt) 2013-12-16 2017-09-26 Genentech Inc conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
UA118113C2 (uk) 2013-12-16 2018-11-26 Дженентек, Інк. Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CR20180243A (es) 2015-10-02 2018-07-31 Genentech Inc Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
JP6852065B2 (ja) 2015-10-20 2021-03-31 ジェネンテック， インコーポレイテッド カリケアマイシン−抗体−薬物コンジュゲート及び使用方法
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
SMT202200490T1 (it) 2017-04-18 2023-01-13 Medimmune Ltd Coniugati di pirrolobenzodiazepina
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
SI3668874T1 (sl) 2017-08-18 2022-04-29 Medimmune Limited Pirolobenzodiazepinski konjugati
ES3075078T3 (es) 2017-09-20 2026-07-27 Ph Pharma Co Ltd Análogos de tailanstatina
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP2022505101A (ja) * 2018-10-18 2022-01-14 ファンダメンタル ファーマ ゲーエムベーハー Ｎｍｄａ受容体媒介毒性を調節するための新規の方法
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
JP7232925B2 (ja) 2019-02-15 2023-03-03 ウーシー バイオロジクス アイルランド リミテッド 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
KR20230132450A (ko) * 2021-01-15 2023-09-15 코히런트 바이오파마 (쑤저우), 리미티드 항trpv6 단일 클론 항체 및 그 응용
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
CN120417934A (zh) 2022-12-23 2025-08-01 基因泰克公司 Cereblon降解剂缀合物及其用途
KR20260012304A (ko) 2023-04-17 2026-01-26 피크 바이오, 인크. 항체 및 항체-약물 접합체 및 사용 방법 및 합성 공정 및 중간체
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof
TW202617186A (zh) 2024-06-28 2026-05-01 美商飛爾富來生物公司 Ｂｃｌ－ｘｌ降解劑抗體結合物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885776A (en) * 1997-01-30 1999-03-23 University Of Iowa Research Foundation Glaucoma compositions and therapeutic and diagnositic uses therefor
US5919638A (en) 1996-10-08 1999-07-06 Abbott Laboratories Reagents and methods useful for detecting prostate tumors
EP1005546A2 (en) * 1997-02-25 2000-06-07 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6194152B1 (en) 1997-08-20 2001-02-27 Dendreon Corporation Prostate tumor polynucleotide compositions and methods of detection thereof
CA2360396A1 (en) * 1998-12-30 2000-07-13 Andrew M. Scharenberg Characterization of a calcium channel family
US6534642B1 (en) * 1999-07-09 2003-03-18 Matthias A. Hediger Compositions corresponding to a calcium transporter and methods of making and using same
WO2001014423A1 (en) 1999-08-19 2001-03-01 Smithkline Beecham P.L.C. Identification of three putative calcium channel vanilrep peptides
WO2001042467A2 (en) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
EP1261708A2 (en) * 2000-01-14 2002-12-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20020072101A1 (en) 2000-01-21 2002-06-13 Gaughan Glen T. Novel human nucleic acid molecules and polypeptides encoding cation channels
AU2001238596A1 (en) * 2000-02-22 2001-09-03 Millennium Pharmaceuticals, Inc. 18607, a novel human calcium channel
US20020156253A1 (en) * 2000-06-26 2002-10-24 Curtis Rory A.J. 48000 and 52920, novel human calcium channels and uses thereof
AU2001247460A1 (en) 2000-03-15 2001-09-24 Millennium Pharmaceuticals, Inc. 18615 and 48003, human ion channels and uses therefor
AU2001285018A1 (en) * 2000-08-17 2002-02-25 Agensys, Inc. Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer
EP1474528A4 (en) 2000-10-13 2006-06-14 Protein Design Labs Inc METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS

Similar Documents

Publication Publication Date Title
GB2366800B (en) Antibody molecules having specificity for human tumor necrosis factor alpha,and use thereof
NO2016006I1 (no) Prodroger av fosfonatnukleotidanaloger,preparat derav og dets anvendelse til terapeutisk og profylaktisk behandling av virusinfeksjoner
CY2016021I2 (el) Στελεχη ιων για την ογκολυτικη θεραπεια του καρκινου
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
AU2002359436A8 (en) Dna amplification and sequencing using dna molecules generated by random fragmentation
AU2002314901A1 (en) Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
KR970704430A (ko) 전립선 질환, 자궁내막증 및 비만증의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of prostatic diseases endometriosis and obesity)
WO2003046207A3 (en) Methods for inhibiting deacetylase activity
ID30116A (id) Turunan-turunan piridopiranoazepin, pembuatannya dan penggunaan terapinya
NO20025241D0 (no) Katalysatorbirer og bÕret metallkatalysator, fremgangsmÕte for fremstilling, samt anvendelse
MA26899A1 (fr) PREPARATIONS CONTENANT UN MEDICAMENT GLUCOCORTICOiDE POUR LE TRAITEMENT DES MALADIES BRONCHOPULMONAIRES.
MXPA03003592A (es) Uso de la tolerancia en el tratamiento del asma.
MXPA03008776A (es) Catalizador para la deshidrogenacion de ciclohexanol y metodo para su preparacion.
NO20043650L (no) Nye, vannloselige porfyrin-platinaforbindelser med hoy tumorselektivitet og deres anvendelse ved behandling av benigne og maligne tumorsykdommer
NO20025265L (no) Regulatorisk nukleinsyre for ABC1-genet, molekyler som modifiserer dets aktivitet og terapautiske anvendelser
AU2001292326A1 (en) Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like
WO2003023027A3 (de) Tt-virus-sequenzen in menschlichen tumorgeweben, mittel zu deren nachweis sowie tumortherapie
AU5689800A (en) Diagnosis, prognosis and treatment of cancer related to the barx2 gene
WO2002089817A3 (en) Anti-virus agent
AU2002213830A1 (en) The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
WO2003020954A3 (en) 205p1b5 in treatment and detection of cancer
NO20030762D0 (no) Forbedret spesifisitet i behandling av sykdommer
WO2004064855A8 (de) Medikament und verwendung zur tumortherapie
AU2002222169A1 (en) Proteins, genes and their use for diagnosis and treatment of chronic asthma
AU2002254524A1 (en) Use of semenogelin in the diagnosis, prognosis and treatment of cancer